About this trial
Target population:
Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility genes.
International multicenter prospective cohort study with randomized intervention (special care follow-up vs. standard care follow-up).
All patients will receive instructions about follow-up at the time point of study inclusion. Patients randomized to the standard care follow-up group will be advised to return annually for follow-up according to current routine practice (without active re-scheduling). In contrast, patients randomized to the special care follow-up group will also be advised to return annually for follow-up but these patients will be actively invited, re-scheduled and reminded by the centers to meet scheduled follow-up appointments.
Eligibility criteria
Qualifiers
None
Disqualifiers
Patients with impaired mental capacity that precludes informed consent.
Pregnancy does not constitute criteria for exclusion from the protocol. However, in pregnant women no Clonidine testing, no PET scanning, MIBG scanning or contrast CT will be performed.
Patients at risk from injury from the MRI magnet due to implantable metal or who suffer from anxiety in enclosed spaces are excluded from MRI.
Trial design
Treatments tested in this trial
- Contact by clinical center
Treatment groups
Sponsors and collaborators
Felix Beuschlein
Lead sponsor
Ludwig-Maximilians - University of Munich
Sponsor institution
Technische Universität Dresden
Collaborator
Wuerzburg University Hospital
Collaborator
University of Zurich
Collaborator
Radboud University Medical Center
Collaborator
Lübeck University Clinic
Collaborator
Ludwig-Maximilians - University of Munich
Collaborator